Literature DB >> 23949791

Alarming incidence of genital mycoplasmas among HIV-1-infected MSM in Jiangsu, China.

J-R Wu1, B Wang, L-S Chen, T Yang, L-J Zhou, Y-X Xie, J-S Xu, H-X Guo, X-P Huan.   

Abstract

Males who have sex with men (MSM) are considered at high risk of blood-borne and sexually transmitted infections (STIs), mainly due to the practice of unsafe sex, often combined with drug use and needle-sharing. A cross-sectional study was designed for the detection of genital mycoplasmas during the period from March 2009 to May 2010 in Jiangsu province. This work was approved by the Research ethics Committee of Jiangsu Centers for Diseases Prevention and Control (CDC), and written consent was obtained from all participants. In total, 243 human immunodeficiency virus-1 (HIV-1)-infected MSM were screened in this study. Over half of them reported a history of sexual activity with females (65.0 %), and 26.3 % reported a history of sexually transmitted diseases (STDs) other than HIV. 44.0 % of patients were in the first 2 years of their HIV infection, and 72.4 % were still in HIV progression. Of the 243 analyzed samples, all were positive for at least one kind of mycoplasma. The infection rates of Mycoplasma genitalium, M. fermentans, M. penetrans, and M. pirum were 25.5, 9.9, 2.5, and 18.5 %, respectively. The M. genitalium infection was associated with a history of sexual activity with females, and those who had sex with females showed higher infection rates. Six  M. penetrans-positive patients were still in HIV infection progression and did not receive highly active antiretroviral therapy (HAART). Men who perform this particular behavior are at higher risk of Mycoplasma infections. Further molecular and epidemiological cohort studies with larger populations are needed in order to identify the role of Mycoplasma infections in HIV-1-infected MSM.

Entities:  

Mesh:

Year:  2013        PMID: 23949791     DOI: 10.1007/s10096-013-1942-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

1.  Conserved terminal organelle morphology and function in Mycoplasma penetrans and Mycoplasma iowae.

Authors:  Dominika A Jurkovic; Jaime T Newman; Mitchell F Balish
Journal:  J Bacteriol       Date:  2012-03-23       Impact factor: 3.490

2.  Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.

Authors:  Constance A Benson; Jonathan E Kaplan; Henry Masur; Alice Pau; King K Holmes
Journal:  MMWR Recomm Rep       Date:  2004-12-17

3.  Lipid-associated membrane proteins of Mycoplasma fermentans and M. penetrans activate human immunodeficiency virus long-terminal repeats through Toll-like receptors.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

4.  Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study.

Authors:  G Perez; J H Skurnick; T N Denny; R Stephens; C A Kennedy; N Regivick; A Nahmias; F K Lee; S C Lo; R Y Wang; S H Weiss; D B Louria
Journal:  Int J Infect Dis       Date:  1998 Jul-Sep       Impact factor: 3.623

5.  A longitudinal study of seroreactivity against Mycoplasma penetrans in HIV-infected homosexual men: association with disease progression.

Authors:  O Grau; P Tuppin; B Slizewicz; V Launay; C Goujard; E Bahraoui; J F Delfraissy; L Montagnier
Journal:  AIDS Res Hum Retroviruses       Date:  1998-05-20       Impact factor: 2.205

Review 6.  AIDS-associated mycoplasmas.

Authors:  A Blanchard; L Montagnier
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

7.  Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation.

Authors:  Takeshi Into; Kazuto Kiura; Motoaki Yasuda; Hideo Kataoka; Nobuo Inoue; Akira Hasebe; Kiyoshi Takeda; Shizuo Akira; Ken-ichiro Shibata
Journal:  Cell Microbiol       Date:  2004-02       Impact factor: 3.715

8.  Coexistence of urethritis with genital ulcer disease in South Africa: influence on provision of syndromic management.

Authors:  R C Ballard; H G Fehler; Y Htun; F Radebe; J S Jensen; D Taylor-Robinson
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

9.  High frequency of antibodies to Mycoplasma penetrans in HIV-infected patients.

Authors:  R Y Wang; J W Shih; T Grandinetti; P F Pierce; M M Hayes; D J Wear; H J Alter; S C Lo
Journal:  Lancet       Date:  1992-11-28       Impact factor: 79.321

10.  Induced mouse spleen B-cell proliferation and secretion of immunoglobulin by lipid-associated membrane proteins of Mycoplasma fermentans incognitus and Mycoplasma penetrans.

Authors:  S H Feng; S C Lo
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more
  3 in total

1.  Clinical Importance of Superior Sensitivity of the Aptima TMA-Based Assays for Mycoplasma genitalium Detection.

Authors:  Kirsten Salado-Rasmussen; Jacob Tolstrup; Farnam Barati Sedeh; Helle Kiellberg Larsen; Magnus Unemo; Jørgen Skov Jensen
Journal:  J Clin Microbiol       Date:  2022-03-23       Impact factor: 11.677

2.  Prevalence and correlates of Mycoplasma genitalium infection among patients attending a sexually transmitted infection clinic in Guangdong, China: a cross-sectional study.

Authors:  Xiao-Hui Zhang; Pei-Zhen Zhao; Wu-Jian Ke; Liu-Yuan Wang; Lai Sze Tso; Zheng-Yu Chen; Yu-Ying Liao; Chun-Mei Liang; Hui-Ru Chen; Xu-Qi Ren; Jin-Mei Huang; Jason J Ong; Fan Yang; Li-Gang Yang
Journal:  BMC Infect Dis       Date:  2021-07-05       Impact factor: 3.090

3.  Association of Mycoplasma fermentans and the risk of HIV-1 infection: A meta-analysis.

Authors:  Yi Liu; Yonghai Dong; Yinghao Wen; Siping Peng; Jie Liao; Yun Liu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.